EPS at Rs 32.19
Demand normalisation post the second wave contributed to the steady growth
Anti-malaria API facility will be operational in 15-18 months
Income declines marginally
It plays a pivotal role in monitoring pharmaceutical pricing
The company has strong product launches both in India and overseas
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
If approved it will bring a second source of MMR vaccine to the US market
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The company has tied up with OrbiMed as a financial partner for global reach
The profits were bolstered by the Boehringer Ingelheim MEK program income
Formulation business grew by 15 per cent in the quarter
KIMS Hospitals' brand, has an aggregate bed capacity of 3,064, including over 2,500 operational beds as of March 31, 2021
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Nearly 6,000 patients have been treated with the drug since 2017
The drug is indicated for mild and transient episodes of heart block
The company posted net profit of Rs.34.24 crores for the period ended June 30, 2020.
PAT rises to Rs 195.76 crore
Subscribe To Our Newsletter & Stay Updated
